EUROAPI Reports First Half Financial Results for 2025
In a recently issued report, EUROAPI highlighted its key financial outcomes for the first half of 2025. The company maintained its commitment to supporting a core EBITDA margin between 7% to 9%, aiming for an upper position of that range through the execution of its strategic plan, known as FOCUS-27.
Net Sales Overview
The first half of 2025 saw net sales reach €412.1 million, reflecting a year-on-year decline of 8.2%. This decrease is primarily attributed to a tough year-on-year comparison, which had been notably influenced by a one-off impact amounting to €21 million in the same period of 2024. If this exceptional situation were excluded, the decrease would have been more moderate at around 4%.
EBITDA and Core EBITDA Performance
Financial Highlights
EBITDA for the first part of 2025 reached €5.0 million, a significant recovery from the negative €1.4 million reported in the first half of 2024. Meanwhile, core EBITDA stood at €39.5 million, translating to a core EBITDA margin of 9.6%, down from 10.6% in the prior year.
Such improvements in EBITDA are celebrated, especially amidst cost-control measures that effectively reduced overall operational expenses. The company indicated it remains committed to maintaining financial discipline and efficiency, essential aspects of its broader strategic framework.
Net Income and Cash Position
EUROAPI reported a net income loss of €28.5 million, which is an improvement compared to the €34.8 million loss experienced during the same period in 2024. Additionally, the company's net cash position at the end of June 2025 amounted to €1.1 million, showcasing a focused approach to managing cash resources.
Impact of Strategic Initiatives
FOCUS-27 Execution
The successful divestment of the Haverhill site to Particle Dynamics marked a pivotal moment in the execution of the FOCUS-27 strategic plan. This divestiture aligns with the company’s objective of optimizing its operational footprint and generating additional revenue streams.
Moreover, EUROAPI has dedicated 60% of its capital expenditures to growth projects, clearly indicating a focus on long-term sustainability and expansion.
Support from Public Aid
In alignment with its objectives, EUROAPI has signed an agreement with the French government, securing up to €140 million in public aid directed at bolstering investments related to the IPCEI Med4Cure project. This pivotal support is aimed at enhancing innovative initiatives and sustaining growth across various sectors.
2025 Outlook Adjustments
Adjusted Financial Forecast
Given the current economic landscape, full-year net sales for 2025 are now expected to decline in the low single digits. This adjustment reflects the anticipated stronger performance in the second half, buoyed by sustained sales in opioid products and a positive uptick in HP API sales.
EUROAPI reaffirms its core EBITDA margin target of 7% to 9% of net sales, expressing confidence in its continued financial discipline and operational efficiency. This commitment is essential as it strives to navigate the unpredictable market environment and bolster its commercial transformation.
Financial Highlights and Key Figures
For an overall understanding of the company’s performance in H1 2025, a summary of key figures reveals:
- Net Sales: €412.1 million
- Core EBITDA: €39.5 million (9.6% margin)
- EBITDA: €5.0 million
- Net Income: €(28.5) million
- Net Cash Position: €1.1 million
Additional Insights for Stakeholders
As the company moves forward, it emphasizes the importance of engaging and collaborating with its key stakeholders to ensure successful execution of its strategic roadmap. The executive team, including CEO David Seignolle, reiterated that they enter the second half of the year with renewed confidence and a solid commitment to advancing its commercial transformation initiatives.
Frequently Asked Questions
What were EUROAPI's net sales in H1 2025?
EUROAPI reported net sales of €412.1 million in the first half of 2025.
How did EBITDA perform compared to H1 2024?
EBITDA significantly improved to €5.0 million from a negative €1.4 million in H1 2024.
What is the company's 2025 outlook?
EUROAPI expects to see a low single-digit decline in full-year net sales for 2025.
How has the company managed its financial position?
The net cash position as of June 2025 was reported at €1.1 million, reflecting ongoing cash management efforts.
What strategic initiatives are in place for growth?
The company has dedicated 60% of its capital expenditures to growth projects and received public aid to support innovation.
